Takeover Potential?, page-3

In the Novartis -see link- study, there were 121 patients, on either Novartis LAG525 with the PD-1 inhibiter or  LAG525 without the PD-1 inhibiter (spartalizumab) The results of the phase I/II study were 1 complete and 11 partial responses - out of 121 patients.This is considered promising.

The Immutep study with TACTI-Mel (Two ACTive Immunotherapies - in Melanoma) is a phase 1 clinical trial using the IMP321 (also called eftilagimod alpha or efti for short), with Mercks Ketyruda a PD-1 inhibiter.... Only 3 cohorts of 6 patients on 1mg, 6mg or 30mg of IMP 321

18 patients were chosen to be part who had no response or little response to Keytruda alone, which sounds like a death sentence....... So far 2 patients have had complete responses -full  remission on both therapies and 11 out of 18....... 61% had partial responses- reduction of tumour size on both therapies. WOW. Some of those who didn't respond may have been on the lowest dose of only 1mg, they have hurriedly started a new cohort on the 30mg which suggests to me the 2 complete responses may have come from the 30mg cohort.

These  Immutep résults are so much better than the Novartis..... I disagree with the last paragraph in the above link and believe this will have Big Pharmas especially Merck jumping.